<DOC>
	<DOCNO>NCT01074944</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety daily ( QD ) versus twice daily ( BID ) dose eliglustat tartrate ( Genz-112638 ) participants Gaucher disease type 1 demonstrate clinical stability BID dose eliglustat tartrate ( Genz-112638 ) . The secondary objective evaluate pharmacokinetics ( PK ) Genz-99067 eliglustat tartrate ( Genz-112638 ) administer QD BID participants Gaucher disease type 1 demonstrate clinical stability BID dose eliglustat tartrate ( Genz-112638 ) .</brief_summary>
	<brief_title>A Study Eliglustat Tartrate ( Genz-112638 ) Patients With Gaucher Disease Evaluate Once Daily Versus Twice Daily Dosing ( EDGE )</brief_title>
	<detailed_description>NOTE : Other Phase 3 study conduct eliglustat tartrate ( Genz-112638 ) GZGD02507 ( ENGAGE ) : NCT00891202 GZGD02607 ( ENCORE ) : NCT00943111</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Eliglustat</mesh_term>
	<criteria>The participant willing provide sign informed consent prior studyrelated procedure . The participant ≥18 year age . The participant diagnose GD 1 confirm documented deficiency acid βglucosidase activity enzyme assay . Female participant childbearing potential document negative pregnancy test prior administration first dose eliglustat tartrate ( Genz112638 ) study . In addition , female participant childbearing potential use medically accepted form contraception throughout study , i.e. , either barrier method hormonal contraceptive norethindrone ethinyl estradiol similar active component The participant meet follow criterion time screening : hemoglobin level ≥9 g/dL ( mean 2 measurement ) ; platelet count ≥70,000/mm^3 ( mean 2 measurement ) ; spleen volume ≤25 multiples normal ( MN ) ; liver volume ≤2.0 MN . The participant consent provide blood sample genotyping Gaucher disease CYP2D6 categorize participant 's predicted rate metabolism , genotyping result already available participant . The participant willing abstain consumption grapefruit , grapefruit juice , grapefruit product 72 hour prior administration first dose Genz112638 throughout duration study . The participant participating GZGD02607 study , `` A Phase 3 , Randomized , MultiCenter , MultiNational , OpenLabel , Active Comparator Study Evaluate Efficacy Safety Genz112638 Participants GD1 Stabilized Cerezyme ® , '' eligible inclusion GZGD02607 ( enrollment ongoing ) access physician participate GZGD02607 , participant participate GZGD02507 study , `` A Phase 3 , Randomized , DoubleBlind , PlaceboControlled , MultiCenter Study Confirming Efficacy Safety Genz112638 Participants GD1 , '' eligible inclusion GZGD02507 ( enrollment ongoing ) access physician participate GZGD02507 . The participant receive miglustat within 6 month prior administration first dose Genz112638 study . The participant partial total splenectomy within 3 year prior randomization . The participant receive pharmacological chaperone miglustat within 6 month prior administration first dose eliglustat tartrate ( Genz112638 ) study . The participant evidence neurologic disorder ( e.g. , peripheral neuropathy , tremor , seizure , Parkinsonism cognitive impairment ) pulmonary involvement ( e.g. , pulmonary hypertension ) relate Gaucher disease . The participant transfusiondependent . The participant document deficiency iron , vitamin B12 , folate require treatment yet initiate , initiate , participant stable treatment least 3 month prior administration first dose Genz112638 study . The participant document prior esophageal varix clinically significant liver infarction current liver enzyme ( alanine transaminase [ ALT ] /aspartate aminotransferase [ AST ] ) total bilirubin &gt; 2 time upper limit normal ( ULN ) , unless participant diagnosis Gilbert Syndrome . The participant clinically significant disease , Gaucher disease , include cardiovascular , renal , hepatic , gastrointestinal , pulmonary , neurologic , endocrine , metabolic ( include hypokalaemia hypomagnesemia ) , psychiatric disease , medical condition , serious intercurrent illness , opinion Investigator , preclude participation study . The participant know following : Clinically significant coronary artery disease include history myocardial infarction [ MI ] ongoing sign symptom consistent cardiac ischemia heart failure ; clinically significant arrhythmias conduction defect 2nd 3rd degree AV block , complete bundle branch block , prolong QTc interval , sustain ventricular tachycardia ( VT ) . The participant test positive human immunodeficiency virus ( HIV ) antibody , Hepatitis C antibody , Hepatitis B surface antigen . The participant receive investigational product ( eliglustat tartrate ( Genz112638 ) ) within 30 day prior administration first dose eliglustat tartrate ( Genz112638 ) study . The participant schedule inparticipant hospitalization , include elective surgery , study . The participant history cancer , exception basal cell carcinoma , within 5 year prior administration first dose Genz112638 study . The participant pregnant lactating . The participant received medication may cause QTc interval prolongation within 30 day prior first dose Genz112638 . Exception : Diphenhydramine ( Benadryl ) medication use premedication ERT infusion allow 7 day prior first dose Genz112638 . The participant receive first time ( i.e. , participant already chronically use ) follow medication within 30 day prior first dose Genz112638 : Strong inhibitor CYP2D6 CYP3A4 ; Inducers CYP3A4 . Exception : Premedications ERT infusion allow 7 day prior first dose Genz112638 . The participant CYP2D6 nonpoor metabolizer indeterminate metabolizer one allele identify active chronically receive strong competitive inhibitor CYP2D6 strong competitive inhibitor CYP3A4 reasonable alternative medication exists . The participant CYP2D6 poor metabolizer indeterminate metabolizer neither allele know active chronically receive strong competitive inhibitor CYP3A4 reasonable alternative medication exists . Exception case : Premedications ERT infusion allow 7 day prior first dose Genz112638 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gaucher disease</keyword>
	<keyword>Genz-112638</keyword>
	<keyword>beta-glucosidase</keyword>
	<keyword>acid β-glucosidase</keyword>
	<keyword>glucocerebrosidase</keyword>
	<keyword>glucosylceramide</keyword>
	<keyword>D-glucosyl-N-acylsphingosine glucohydrolase</keyword>
	<keyword>substrate reduction therapy</keyword>
</DOC>